Repligen Corp (RGEN) is a publicly traded Healthcare sector company. As of May 20, 2026, RGEN trades at $108.55 with a market cap of $5.88B and a P/E ratio of 117.84. RGEN moved -1.01% today. Year to date, RGEN is -33.97%; over the trailing twelve months it is -14.00%. Its 52-week range spans $100.99 to $182.52. Analyst consensus is strong buy with an average price target of $176.23. Rallies surfaces RGEN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for RGEN, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $108.55 |
| Market Cap | $5.88B |
| P/E Ratio | 117.84 |
| EPS | $0.92 |
| Dividend Yield | 0.00% |
| 52-Week High | $182.52 |
| 52-Week Low | $100.99 |
| Volume | 291.67K |
| Avg Volume | 0 |
| Revenue (TTM) | $763.34M |
| Net Income | $51.40M |
| Gross Margin | 52.90% |
15 analysts cover RGEN: 0 strong buy, 12 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $176.23.